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Current diagnostic tools being used for tuberculosis lack the speed and sensitivity necessary to 
successfully combat the current tuberculosis epidemic.  Real-time Polymerase Chain Reaction, 
RT-PCR, can provide the rapid and specific diagnosis that is currently in demand in the global 
community.  Its disadvantage is that due to the waxy and robust nature of the M. tuberculosis 
membrane, not enough genomic DNA is present to provide for amplification in a RT-PCR. It 
was previously found in our laboratory that hydrolysis of one of abundant glycolipid of 
mycobacterial envelope, Trehalose, 6,6’-dimycolate, by a recombinant TDM-specific hydrolase 
caused rapid lysis of cell (Yong et.al. manuscript submitted).  In this study, we tested if rapid 
lysis by TDM-specific hydrolase (rTDMH) can be exploited in conjunction with the RT-PCR to 
develop a sensitive diagnosis of tuberculosis. 
Results demonstrated that by incubation of both attenuated M. tuberculosis, and virulent 
M. tuberculosis with rTDMH for lysis and subsequent usage of this lysate in a RT-PCR assay, 
yields sensitive amplification of mycobacterial DNA.  rTDMH-mediated lsyis could facilitate 
amplification of even 10 bacilli, the rTDMH treated cells show amplification while lack of 
treatment failed to detect these bacilli  These results were consistent in in-vitro liquid culture and 
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 v 
in complex sputum samples spiked with the mycobacteria, showing that incubation with rTDMH 
can improve the sensitivity of the RT-PCR.  
Statement of Public Health relevance:  Using rTDMH with RT-PCR as an improved 
diagnostic tool for tuberculosis due to the rapid, accurate and sensitive nature of the assay could 
provide the global community with a much better method of diagnosing a disease that has 
plagued the world for thousands of years. Tuberculosis infects 9 million people and kills 3 
million people every year and presently one-third of the world’s population is infected with it.  A 
better diagnostic tool could result in reducing the spread of disease; reducing the mortality 
associated with disease, especially in HIV infected individuals; and on a broader scale, could 
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1.0  INTRODUCTION 
1.1 THE TUBERCULOSIS EPIDEMIC 
Mention the disease tuberculosis to any person and they most assuredly have heard of it.  
Tuberculosis is not a novel disease that has yet to capture the attention of the general public.  In 
fact, it has had a presence in the global community for thousands of years.  Skeletal remains 
dating from as early as 4000BC show the existence of tuberculosis, and tubercular decay has 
been found in the spines of mummies from 3000-2400BC.  As tuberculosis presents a variety of 
symptoms, it was not until the 1820s that it was identified as a unified disease, and in 1839 it was 
formally labeled tuberculosis by J.L. Schonlein[1].  That being said, there is still a sense of 
apathy that exists about it, and perhaps this is due to its silent nature and that its presence is not 
pronounced as much as others.  As research on tuberculosis has progressed, the way in which it 
is viewed has in turn changed to looking at it as a spectrum, one end being asymptomatic, 
noninfectious disease to the other end being, infectious and symptomatic.  This characteristic of 
tuberculosis is what makes it challenging to address.  Nevertheless, the impact of this disease is 
notable, and more attention must be allotted to it. 
 Presently, one-third of the world’s population is infected with tuberculosis and thus it is 
one of the most wide-spread diseases[2].  The World Health Organization projects that 
approximately one billion people will be infected with tuberculosis between the years of 2000 
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and 2020.  Annually, over nine million people around the world become infected, and there are 
approximately two to three million deaths that are directly attributable to tuberculosis[3].  
Moreover, tuberculosis, AIDS, and malaria are responsible for over half the deaths due to 
infectious diseases each year.  In some cases these deaths arise from co-infections, where the 
individual is infected with both tuberculosis and HIV.  When observing the global impact of 
disease, there appears to be a socio-economic trend associated with it. The highest incidences are 
seen in countries with the lowest gross national products, this being predominantly in regions of 
Africa, Eastern Europe, South East Asia, Asia, and parts of South America.  A particular burden 
is seen in sub-Saharan Africa, with ≥300 new cases per 100,000[2].  Figure 1 demonstrates the 
global burden of disease and includes all forms of tuberculosis, including multi-drug resistant 
(MDR-TB) and extremely drug resistant tuberculosis (XDR-TB).  
 
Figure 1: Global Incidence of TB in 2010 (World Health Organization) 
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The prevalence of MDR-TB and XDR-TB continues to increase in the global community.  
MDR-TB is a form of tuberculosis that has adapted a tolerance to at least two of the best 
antibiotics used as treatment, isoniazid and rifampicin.  XDR-TB is, in turn resistant to the 
previously mentioned first-line drugs as well as any fluoroquinolone and at least one of three 
injectable second-line drugs (i.e., amikacin, kanamycin, or capreomycin)[4].  Of the new cases of 
tuberculosis 3.3% are MDR-TB.  Figure 2 depicts the global burden of MDR-TB and XDR-
TB[5]. 
 
Figure 2: Global Burden of MDR-TB and XDR-TB (World Health Organization) 
 
When comparing Figures 1 and 2, there is an interesting difference to note.  In Figure 1, 
the highest burden of disease is in Africa, whereas when evaluating the global burden of MDR-
TB and XDR-TB, the highest is seen in Eastern Europe, Asia and South East Asia.  This may be 
because accessibility of antibiotics may be higher in Eastern Europe, Asia versus Africa, thus 
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increasing the likelihood that drug resistance may appear, or because surveillance may not be as 
good in parts of Africa and thus the true numbers are underrepresented.  
 Tuberculosis has a significant presence in the HIV-infected community as well.  It is the 
leading cause of death amongst persons with HIV infection[6]. In fact, almost one in three deaths 
amongst people with HIV are due to tuberculosis.  People who have both HIV and latent 
tuberculosis are 20 to 30 times more likely to develop active tuberculosis[7].  In 2009, there were 
9.4 million new cases of tuberculosis, of which 1.2 million (13%) were among people living with 
HIV[6]. The highest burden of HIV in new tuberculosis cases is in sub-Saharan Africa (see 
Figure 3).  
 
 
Figure 3: Estimated HIV prevalence in new TB cases in 2010 (World Health Organization) 
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2.0  BACKGROUND: THE TUBERCULOSIS DISEASE 
2.1 PATHOGENESIS  
M. tuberculosis, is the causative pathogen for disease tuberculosis.  M. tuberculosis is a 
bacterium that typically attacks the lungs; however, it potentially can attack any part of the body 
such as the kidney, spine, and brain.  If left untreated, tuberculosis can be fatal.  Tuberculosis is a 
droplet infection spread from person to person through the air[8].  When an infected individual 
coughs, sneezes, and sings, droplets containing the bacteria may be introduced into the air and 
surrounding individuals may be exposed to said droplets and unknowingly inhale the air 
containing them and become infected.  Tuberculosis infections begin as the mycobacterium 
begins to replicate in the small air sacs of the lungs, and from there, some may enter the blood 
stream and spread throughout the body [9].  
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Figure 4:Phases of infection of M. tuberculosis (Rook, Dheda, & Zumla) 
Infection of M. tuberculosis produces a spectrum pathology.  Historically, it was thought 
that there were two forms of tuberculosis, latent and active; now it is becoming more apparent 
that these are the two ends of the spectrum.  The latent form is non-infectious and can reside in 
the host’s body dormant for years, if not his lifetime.  It is asymptomatic and cannot be spread 
from person to person. However, an asymptomatic infection is always at risk for it becoming 
active and various stressors on the body may cause this such as immune suppression with HIV.  
The infected individual will test positive with the skin or blood test; however sputum smears and 
chest x-rays will be negative [10]. 
  The active disease causing, form is when it is reproducing in the host. In this scenario, 
the host is presenting symptoms of disease and is infectious, meaning the host may further infect 
others, further propagating the disease.  This individual will test positive if given the skin test or 
blood test and may have an abnormal chest x-ray or positive sputum smear or culture. A person 
may have one of two different subsets of the disease, pulmonary or extrapulmonary.  Typically, 
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tuberculosis infection occurs in the lungs (pulmonary); however, as aforementioned it can be 
found in other parts of the body (extrapulmonary) [10].  
2.2 MYCOBACTERIUM TUBERCULOSIS CELLULAR STRUCTURE 
M. tuberculosis belongs to the genus mycobacteria, which are actinomycetes. A separate 
classification for mycobacterial species is primarily because of their acid-fast staining that 
originates from their unique envelope structure. The mycobacterial cell envelope is divided in 
distinct layers of plasma membrane, a core cell wall complex and a membrane-like outer layer 
made of extractable lipids.  In fact, over 60% of the cell envelope is comprised of lipid, which 
provides intrinsic tolerance to many antibiotics, and resists against killing by acidic and alkaline 
compounds, osmotic lysis via complement deposition, resistance to lethal oxidations and survival 
inside macrophages [11]. See Figure 5 for a schematic diagram of the cell envelope. 
 
Figure 5: Schematic diagram of the cell envelope of M. tuberculosis (Park & Bendelac) 
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2.2.1 Trehalose 6,6’-dimycolate (TDM) 
One of the most abundant extractable lipid of the envelope is Trehalose 6,6’-dimycolate 
(TDM), which is responsible for the cording morphology of the virulent M. tuberculosis [12]. 
 
2.2.2 TDM hydrolase 
A hydrolase of TDM, rTDMH, was discovered in Mycobacterium smegmatis called 
Msmeg_1529.  M. smeg.is commonly used in laboratory work to research other mycobacteria 
such as M. tuberculosis because of its similarity; however, it has attractive qualities, such as 
being non-pathogenic, growing faster and able to be used at a BSL-1 level.  This species shares 
more than 2000 homologs with M. tuberculosis and has the same unique cell membrane 
structure.  This discovery prompted the search for the similar hydrolase in M. tuberculosis.  Such 
a hydrolase was found, subsequently isolated and M. tuberculosis culture was then treated with 
rTDMH and results showed that rTDMH was able to successfully, disrupt the cellular membrane 
and thus lyse M. tuberculosis [12].  This was done in Dr. Anil Ojha’s lab following a process by 
which 106 M. tuberculosis bacilli were incubated with various concentrations of recombinant 
rTDMH for 2 days in phosphate buffer saline with Tween- 80, PBST.  It was found that the 
viability of the population was reduced by 100-fold or more with 0.8uM or higher concentrations 
of the enzyme.  It was also done in various other media environments including a detergent free 
Sauton’s media agar plate. This was done, in particular, to exclude the impact that tween-80 may 
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have on the mycobacterial envelope [12].  The results were overwhelmingly supportive of 
rTDMH’s ability to reduce mycobacterial viability.  The results can be seen in Figures 6 and 7 
below where TDMH was spotted on a lawn of M. tuberculosis and buffer on another as a control. 
 
   
Figure 6: Buffer treated bacilli on Sauton's agar plate 
 
Figure 7: TDMH treated bacilli on Sauton's agar plate 
 
2.3 DIAGNOSIS  
Diagnosing an individual with tuberculosis follows a series of tests and steps that consist of 
medical history examination, tuberculin skin test, chest x-ray and bacteriologic examination.  
 10 
What the majority of the population recognizes and has experienced is the tuberculin skin test.  
This test can recognize latent tuberculosis as well as active; however further testing must be done 
to confirm infectious tuberculosis infection. The test is performed by injecting a small amount of 
fluid called tuberfulin into the skin in the lower part of the arm.  The test is read in 48 to 72 hours 
by a trained health care professional who looks for an induration on the arm.  An induration is a 
hard, raised area where the injection was.  What determines a positive result is the size of the 
reaction to the site. It also depends on the individual’s risk factors for infectious tuberculosis and 
progression to tuberculosis disease such as immunosuppression or exposure to other tuberculosis 
infected individuals.  The disadvantage of the skin test is that it may produce false negatives, 
especially if the individual is co-morbid with sacoidosis, Hodgkin’s, lymphoma, and malnutrition 
[13].   
If said individual tests positive with the skin test, a chest x-ray is performed to rule out 
pulmonary disease. A posterior-anterior chest radiograph is used to detect chest abnormalities.  
Lesions may appear anywhere in the lungs and may differ in size, shape, density and cavitation.  
These abnormalities may suggest tuberculosis infection but cannot definitively diagnose it.  
 Sputum samples are gathered and examined for tuberculosis via acid fast bacilli (AFB) 
using microscopy.  AFB is rather simple and quick but again it cannot confirm the presence of 
M. tuberculosis as some acid-fast bacilli are not M. tuberculosis.  Individuals with positive AFB 
smears are considered infectious, and then a culture is grown to definitively identify if the 
pathogen is M. tuberculosis [14]. The sputum culture is the cornerstone trademark test for 
definitive diagnosis of tuberculosis.  The culture is grown in 7H9 broth or on 7H10 or 7H11 agar 
plate. Following this, the specimen may be tested for drug susceptibility, which requires an 
additional four weeks of testing.   
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There are challenges associated with using sputum cultures as a diagnostic tool.  One 
such challenge is that the mycobacterium is very slow growing and it may take four to 12 weeks 
for the blood or sputum culture to grow. It is imperative to look at the HIV-infected community 
as a separate cohort as it is affected by tuberculosis differently.  There are several drawbacks of 
this tool that are more specific to HIV-infected individuals.  Tuberculosis is often difficult to 
diagnose in HIV-infected individuals because of the presence of nonspecific symptoms, atypical 
or normal chest radiograph findings. First, HIV-infected individuals do not produce much 
sputum and the bacterial count may be low, thus resulting in false negatives in sputum cultures.  
Second, because of the amount of time it could possibly take to diagnose someone, or the 
possibility of a false negative, the individual may be put on antiretroviral therapy (ART) for 
HIV, which could induce the latent tuberculosis to become active [15].  In addition to this, the 
potentially infected individual may have active tuberculosis and be exposing others to the 
disease, particularly other HIV-infected individuals with compromised immune systems when 
they go to a clinic for example [14]. 
When evaluating diagnostic tools, they should be examined for the following qualities: 
sensitivity, specificity, predictive value, speed, reproducibility, cost effectiveness, safety and 
simplicity.  As far as laboratory techniques are concerned, there are various others that may be 
used for the recognition of tuberculosis, two of which were previously mentioned, AFB and 
sputum culture.  However, in addition to those, there are others that may be potential candidates.    
Others that exist include those that are used through methods of culturing such as, micro colony 
detection on solid media; septi-AFB method; radiometric BACTEC 460; MGIT 960 
mycobacteria detection system; MB/BacT system; ESP culture system II; microscopic 
observation of broth cultures [14]. As aforementioned, one consistent disadvantage with these 
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culture techniques is that the minimum time required is at least two weeks and may take up to 12 
weeks.   For the purpose of this paper, only those that are used for the detection of M. 
tuberculosis directly from clinical samples will be detailed. 
 There are other methods that are used as an alternative to smears. There is the phenotypic 
method, in which there is the FAST plaque technique which is a phage based technique which 
uses a mycobacteriophage to detect the presence of M. tuberculosis directly from sputum 
samples. There is Capture ELISA which can be used in the detection of tuberculosis in urine and 
this technique has 93% sensitivity and 95% specificity [14].  Detection of LAM in sputum 
samples is another that is based on the capture antibody from a murine source (murine 
monoclonal antibody against LAM).  The rabbit anti-serum against M. tuberculosis is used as a 
source of detection against LAM in sputum.  Next, there is antigen detection in bodily fluids. 
Here, free mycobacterial antigen at a specific concentration can be detected in biological fluids 
such as cerebrospinal fluid. The sensitivity here is from 40-50% and specificity is 80-95% [13].   
 Recently, nucleic acid amplification was integrated into the diagnostic algorithm of TB. 
This technique was further improved by molecular-beacon-based real-time polymerase chain 
reaction, or RT-PCR.  RT-PCR is a technique by which specific, target DNA is simultaneously 
amplified and quantified. PCR entails the use of a pair of primers that are complementary to a 
defined sequence on each of the two strands of the DNA. These primers are extended by a DNA 
polymerase such that a copy is made of the designated sequence. After making this copy, the 
same primers can be used again, to make not only another copy of the input DNA strand but also 
of the short copy made in the first round of synthesis. This leads to exponential amplification. 
This process is done through a series of heating and cooling to extend and anneal [14].   
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The components necessary to perform a RT-PCR in this study are the sample DNA, 
molecular probe, Applied Biosystems Taq Man master mix (contains the polymerase), forward 
and reverse primers.   The primers used are tuberculosis specific 16s rRNA primers.  16s rRNA 
is used for phylogenetic studies; it is highly conserved between different species of bacteria and 
archaea and also contains hypervariable regions that can provide species-specific signature 
sequences useful for bacterial identification.  This is why is it used in bacterial identification in 
RT-PCRs and what makes RT-PCRs able to be so specific. The molecular beacon probe is a 
short oligonucleotide probe with a loop-and-stem structure.  One portion of it is labeled with a 
fluorophore and the other with a quencher [16,17].  The loop contains a sequence that is 
complimentary to the wild-type sequence of M. tuberculosis. When the complementary sequence 
is recognized it anneals to the amplicon on the beacon and will fluoresce.  
In comparison to the other two techniques commonly used in tuberculosis diagnosis, 
AFB microscopy and sputum culture, the RT-PCR is a more rapid, specific and reliable 
technique, taking less than a day to attain results. However, it has one particular limitation which 
is highly relevant in the context of mycobacteria. The sensitivity of the technique is dependent on 
the efficiency of the DNA extraction from the target organisms. The robust membrane makes it 
difficult to lyse the mycobacteria by simple detergent such that DNA is exposed and as a result 
more mycobacteria are required to elicit ample amplification in the PCR.  Therefore, an efficient 
lysis of M. tuberculosis is important for sensitive diagnosis of Tuberculosis. Until then, although 
this technique is promising, it will have this aforementioned drawback.  
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2.4 PUBLIC HEALTH SIGNIFICANCE 
Tuberculosis remains a significant concern in the global community for many reasons, mostly 
because of the sheer magnitude of its reach.  It continues to become a more complex problem 
with the emergence of its drug resistant varieties, MDR-TB and XDR-TB.  With millions 
currently infected with the disease and millions more being infected each year, it is imperative to 
address this problem. Due to the nature of the pathogen, and its disproportionate effect 
socioeconomically speaking, it has been quite difficult to control and eliminate. In resource 
limited areas, the disease has a higher burden because of poor surveillance (in diagnosis), poor 
living conditions, treatment availability, and co-infection with other pathogens such as HIV. 
 One of the ways in which it can be addressed is by developing a better diagnostic tool for 
it.  If a more sensitive and rapid tool was available, cases of tuberculosis could be identified 
more quickly and subsequently isolated and treated, thus preventing further spread of the disease 
and hopefully decreasing mortality rates.  A better diagnostic tool, particularly in HIV infected 
individuals, could also significantly reduce deaths related to tuberculosis, which, as 
aforementioned, is responsible for one out of every three deaths [3].   
With that being said, if the envelope of Mycobacterium tuberculosis could be disrupted 
such that bacterial DNA was released, this lysate could be used in conjunction with RT-PCR as a 
more sensitive and rapid diagnostic tool.  The study explored whether through the use of an 
enzyme, TDMH, the bacterial membrane could be disrupted and then used in a RT-PCR, 
resulting in greater amplification. 
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3.0  THESIS AIMS 
Tuberculosis affects more than just those who are infected with the causative pathogen, but also 
has an economic burden and puts others, especially vulnerable populations, at risk for disease.  
There is a clear demand for a better diagnostic tool to identify M. tuberculosis.  Existing 
diagnostic tools, such as sputum culture, are time intensive and not accurate enough to address 
the needs of the community.  RT-PCR is an attractive tool for the diagnosis of tuberculosis 
because of its sensitivity, specificity, and rapid nature.  As a result, finding a way to use it 
successfully is desired.   
It is known in our lab that the TDM-hydrolase can be used to remove the TDM glycolipid 
that is abundantly present on the membrane such that the envelope is disrupted leading to cellular 
lysis.  The purpose of this study is to explore whether the product of this lysis, the lysate, could 
be successfully used in a RT-PCR scenario and provide improved amplification.  If this indeed 
worked, it could be used as a diagnostic tool for M. tuberculosis.   
The three chief aims of this thesis begun with developing the enzyme, rTDMH and 
testing its activity after which the first was, testing its effectiveness with the attenuated form of 
M. tuberculosis, MC2 7000 and running a RT-PCR.  Second, testing if the enzyme is effective in 
more complex samples such as sputum, using MC2 7000.  The final aim was examining the 
effectiveness of the enzyme in virulent M. tuberculosis in sputum samples. 
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Hypothesis:  Can we use the rTMDH-mediated lysate of M. tuberculosis with the RT-
PCR assay to enhance the assays sensitivity? 
AIM #1: Test the utility of rTMDH in RT-PCR based detection of M. tuberculosis 
using liquid culture of attenuated M. tuberculosis. 
AIM #2:  Test the utility of rTDMH in simulated sputum sample spiked with 
attenuated M. tuberculosis in RT-PCR 
AIM #3:  Test the utility of rTDMH in simulated sputum sample spiked with 
virulent M. tuberculosis in RT-PCR 
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4.0  MATERIALS AND METHODS 
4.1 MYCOBACTERIAL STRAINS USED 
The mycobacteria used take a week to grow after the culture is passaged. When cells die, they 
are lysed, or broken open and cellular components including DNA are released. Because of this, 
younger cultures are used for the experiments.  The amount of bacteria present in culture is 
determined by using a spectrophotometer.  The desired optical density for the experiments was 
approximately 0.5.  
4.1.1 M. tuberculosis: mc2 7000  
mc2 7000 is the attenuated form of M. tuberculosis. and thus is a biosafety level 2 approved 
agent.  The culture is grown at 37 degrees Celsius in a 50ml polystyrene bottle containing 
7H9OADC media with 0.05% tween and pantothenic acid (100mg/ml).   
4.1.2 Virulent M. tuberculosis (Edmonds) 
Virulent mycobacteria are non-attenuated and pathogenic and due to its dangerous nature, it must 
be used in a biosafety level 3 laboratory.  The culture is similar to that of its attenuated form 
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however, with the omission of pantothenic acid. Thus the culture is still grown at 37 degrees 
Celsius in a 50ml polystyrene bottle consisting of 7H9OADC media with 0.05% Tween. 
 
4.2  SPUTUM 
Dr. Anil Ojha PhD, had and has a standing IRB to obtain sputum samples for the studies.  The 
sputum samples were provided by Dr. William Pasculle from UPMC.  The samples did not have 
bacteria in them upon receiving them; they were later spiked with one of the two mycobacteria 
for the purpose of the experiment.  Samples were stored at 4 degrees Celsius and placed on ice 
when they were removed.    
4.3 AIM #1: TEST THE UTILITY OF RTMDH IN RT-PCR BASED 
DETECTION OF M. TUBERCULOSIS USING LIQUID CULTURE OF ATTENUATED 
M. TUBERCULOSIS.     
4.3.1 Protocol for the development of rTDMH enzyme 
4.3.1.1 Transformation protocol  
50ul of competent E. coli cells were taken from -80 degrees Celsius freezer and 1ul of plasmid 
was added and mixed very gently. This was then placed in a 42 degrees Celsius water bath for 
one minute, after which, it was placed back on ice for two minutes. This temperature shock 
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enabled the plasmid to enter the E. coli, by disrupting the membrane.  Following this, 1 ml of LB 
broth was added and placed on a shaker for 1 hour at 37 degrees Celsius. Next, it was spun down 
at 5K rpm for five minutes; 800ul were removed and the pellet was resuspended in the remaining 
liquid.  The cells were then plated out on LB+CB agar plates for 12 to 18hrs.  Carbenicillin, CB, 
is a bacteriolytic antibiotic used for selection. Only those colonies that are resistant to the 
antibiotic will remain, and those colonies are the ones that contain the plasmid.  After, the 
colonies were scraped and placed in 2ml LB broth and placed on 37 degree shaker overnight.   
The next day the sample was transferred to a flask containing one liter of LB broth and 
1ml CB and placed on 37 degree Celsius shaker for three to four hours or until the optical 
density, o.d., read 0.6 to 0.8.  After, IPTG was added (for .24 grams of IPTG in 1ml) and placed 
on 30 degree Celsius shaker at 160 rpm for 3 hours.  The cells were spun down in four different 
bottles at 10K rpm for five minutes at 4 degrees Celsius and the supernatant was removed.  After 
this, 10ml lysis buffer + 100ul imidazole were added to the cell pellet and resuspended and 
placed on ice for 30 minutes then sonicated 10 times.  The sonication process entailed 10 
seconds of sonication then 20 seconds on ice.  After this the samples were spun down at 
1200rpm for 30 minutes at 4 degrees Celsius.  While the samples were being spun the agarose 
that would be later used was made.   It involved combining 2ml agarose and 10ml binding buffer 
and this was washed 3 times.  The final time the supernatant was removed and just the agarose 
remained.  
The supernatant of the sonicated cells that were spun down for 30 minutes was added to 
the agarose and resuspended and put on a rotary at 4 degrees Celsius for one hour after which the 
sample was spun down at 4 degrees Celsius for five minutes at 2000 rpm and washed five times 
with 5ml of wash buffer.  The final time, the pellet was resuspended in 4ml of wash buffer.  This 
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product was then transferred to a column and placed over a glass tube to let it run through and 
the elution buffer was added in 500ul increments and let run through in separate microcentrifuge 
tubes seven times.  The elution is done by Ni2+ chromatography; in which, the protein is His-
tagged which binds to the beads and allows the rest to flow through.  The protein is then eluted 
our by using imidazole containing elution buffer to release it from the beads. A SDS PAGE gel 
was run and three lanes were chosen that had the most heavily concentrated bands and those 
were used for the dialysis. 
 
4.3.1.2 Dialysis 
Dialysis is a method used to concentrate the enzyme in glycerol.  A spectra/por dialysis reservoir 
was filled with a large volume of the appropriate dialysis buffer.  The dialysate volume was 100 
times the sample volume. (Example: 10ml sample 1 L of dialysate).  The reservoir was a 
larger 2L beaker.  Following this, the dialysis tubing was cut into appropriate lengths; the closure 
was opened.  The tubing was then inserted into the opened closure and re-clamped with 
approximately 3 to 5 mm extending from the closure.  After this, the sample was loaded into the 
dialysis tubing through the open end and adjusted for length.  The tubing was clamped 
perpendicular to the previous with the second closure.  Next, the dialysis sample was placed in 
the appropriate dialysis buffer and a clean magnetic stir bar was dropped into the dialysis 
reservoir and placed at 4 degrees Celsius overnight.  The next day it was transferred to a fresh 
centrifuge tube and immediately stored at -20 degrees Celsius.   
The concentration of the enzyme was determined by using a spectrophotometer set at 
260nm. Standards using BSA were measured by the spectrophotometer and plotted to develop a 
trendline and subsequent equation to determine the concentration of the measured sample.   
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4.3.2 Protocol for testing the activity of the rTDMH enzyme 
4.3.2.1 Plating rTDMH on 7H11 agar plates in comparison to standard control of storage 
buffer 
50ug of rTDMH were added to 107 mc2 7000 bacteria, and stored overnight at 37 degrees Celsius 
and the following day serial dilutions were made. Corresponding volume of storage buffer was 
added to another set of 108 mc2 7000 cells as a comparison.  10ul of each dilution was plated out 
on 7H11 agar plate and left for two weeks in a 37 degree Celsius incubator.  See Figure 8 for a 











4.3.3 Protocol for genomic DNA preparation and isolation using rTDMH 
The stock concentration of rTDMH used was 13ug/ul.  109 cells were taken and washed with 




Figure 8: Diagram of Enzyme Testing on 7H11 agar plates by dilution factor 
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used as it was determined to be the optimal buffer for rTDMH in comparison to PBS, PBS-
tween, and NaCl.  20ul or 260 ug of rTDMH was added to one microfuge tube and placed on a 
rotator for two hours at 37 degrees Celsius.  In a corresponding tube, 20ul of storage buffer was 
added to 109 cells in PBS-A as a standard control.    
After two hours, 100ul of 10% sodium dodecyl sulfate (SDS) was added and mixed 
gently after which 10ul of 50mg/ml proteinase K was added, gently mixed, and placed at 55 
degrees Celsius for 30 minutes.  Following this, 200ul of 5M NaCl was added and gently mixed.  
NaCl blocks the binding of DNA to centrimide, which is present in the CTAB solution.  At this 
point, the CTAB was preheated at 65 degrees Celsius and then 160ul of it was added to the 
sample, gently mixed and placed at 65degrees Celsius for 10 minutes.  An equal volume of 
Chloroform: isoamyl alcohol (24:1 ratio) was added and shaken gently to mix and spun for five 
minutes at high speed. 900ul of the supernatant was transferred to a fresh microfuge tube and the 
extraction was repeated this time 800ul of the aqueous layer was transferred to a fresh microfuge 
tube.  To the 800ul, 560ul (0.7 x the vol) of isopropanol was added and mixed via inversion until 
DNA had precipitated out of solution.  Then the sample was incubated at room temperature for 
five minutes after which it was spun down at max speed for 10 minutes and the supernatant was 
removed and 1ml of 70% Ethanol was added to wash the DNA pellet and once again was spun at 
max speed for five minutes.  The supernatant was removed and the pellet was allowed to air dry 
and then covered with 50ul of TE buffer and an electrophoresis gel was run to verify presence of 
DNA.  
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4.3.4 Incubating attenuated form of M. tuberculosis, mc2-7000 with rTDMH and 
subsequently run RT-PCR with sample Incubation Protocol 
4.3.4.1  Incubation Protocol 
First 109 cells were attained. 1ml of growing culture was taken and the optical density (o.d.) was 
measured.  An o.d. of 4 means 109 cells.  To achieve 109 bacteria, 4 was divided by the measured, 
o.d.  
 Example:  o.d.= x  4/x= #ml needed to reach 109 cells 
The cells were subsequently spun down at 5K rpm for 10 minutes and the supernatant 
was discarded.  The cells were resuspended in 10ml of PBS (to wash cells), and spun again at 5K 
rpm for 10minutes.  Once again the supernatant was discarded, and cells were resuspended in 
1ml PBS-Asparagine (4g/L) and transferred to 1.5ml microfuge tube.  The desired dilutions were 
then made.  Of the dilutions, 10ul of each dilution was placed into a microfuge tube. 1ul of 
rTDMH (or 11 -17 ug) was added to each of the samples.  For the non-protein control, 1ul (or 
corresponding volume) of storage buffer was added to matching sample set.  The samples were 
then incubated at 37 degrees for 30 minutes. Following incubation the samples were removed 
and placed on a 75 degree hot plate for 20 minutes to inactivate the enzyme or any other cellular 
components or nucleases that could inhibit the reaction.  Following this, the RT-PCR was set up  
4.3.4.2 RT-PCR protocol  
The protocol was completed on ice and in a dimly lit room as the molecular probe is light 
sensitive. The RT-PCR reaction had a total volume of 10ul. After samples were loaded to the 
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wells and covered, the plate was wrapped in foil to protect it from light. The components of the 
RT-PCR are as follows: 
 1ul of sample.  
 5ul Applied Biosystems Taqman master mix 
 4ul Millipore water 
 0.2 16S ul Molecular beacon probe (commercially available from Sigma-
Aldrich) 
 0.1ul 16SRNA primer (Forward and Reverse primer mix)  
RT-PCR Conditions for Applied Biosystems master mix (Using Applied 
Biosystems RT-PCR machine in Dr. Alice Tarun’s, PhD, lab) 
o 95 degrees 30 sec, 58 degrees 1min, 72 degrees 30 sec * 40 cycles  
RT-PCR Samples 
The dilutions used were the following: bacteria per 10ul RT-PCR reaction: 104, 103, 102, 10, and 
1. Data from the RT-PCR were plotted in an excel graph to compare the results between the 
storage buffer standard and the rTDMH treated bacteria.  “NC” is negative control, “Protein” 
was the TDMH treated, “Buffer” was the storage buffer standard treated, and “PC” was the 
positive control, which consisted of purified genomic DNA.  
4.3.4.3 Confirmatory Gel Electrophoresis  
The electrophoresis gel separates segments of DNA by size via a current.  Because DNA is 
negatively charged, the DNA will “run” through the gel from the anode to the cathode.  Larger 
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pieces run slower than smaller and through this the pieces are separated by size.  A standard 
ladder was run in one lane so that the size of the bands present in the sample could be 
determined. The gel that was run was a 1% Agarose gel and the components of which were as 
follows: 
• 0.5 grams Standard Agarose 
• 50 mL TBE buffer 
These components are heated in a microwave for one minute, after which 0.4ul ethidium 
bromide was added, mixed thoroughly and added to the gel mold. After solidified it was placed 
in the apparatus in TBE buffer and 5ul of sample were added per well, with 3ul of a 100 base 
pair ladder added as a standard comparison to identify the size of the DNA.  
4.4 AIM #2: TEST THE UTILITY OF RTDMH IN SIMULATED SPUTUM SAMPLE 
SPIKED WITH ATTENUATED M. TUBERCULOSIS IN RT-PCR 
4.4.1 Spiking Sputum Samples with mc2 7000 
First 109 cells were obtained. 1ml of growing culture was taken and the optical density (o.d.) was 
measured.  An o.d. of 4 meant 109 cells.  To achieve 109 bacteria, 4 was divided by the measured, 
o.d. The o.d. of the bacteria used was 0.482 
 Example:  o.d.= x  4/x= #ml needed to reach 109 cells 
The cells were subsequently spun down at 5K rpm for 10 minutes, and the supernatant was 
discarded.  The cells were resuspended in 10ml of PBS (to wash cells), and spun again at 5K rpm 
for 10 minutes.  Once again, the supernatant was discarded and cells were resuspended in 1ml 
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PBS-Asparagine (4g/L) and transferred to a 1.5ml microfuge tube.  The desired dilutions were 
then made.  The sputum samples were spiked with the desired dilution value in 450ul of sputum.  
For example, if the dilution made was 108 then 50ul was added to 450ul of sputum to achieve a 
value of 107 bacteria per ml of sputum.  The dilutions made were 106, 105, 104, 103 per ml of 
sputum. 
4.4.2 Protocol for Clarification of Sputum 
First, a decontamination fluid was made by mixing equal volumes of sterile 1M NaOH solution 
and 0.1M sodium citrate, and then 5mg N-acetyl-L-cysteine was added per ml.  One volume of 
decontamination fluid was added per volume of sputum sample and placed on shaker at 25 
degrees Celsius for 20 to 25 minutes, after which the samples were spun down at 12K x g for 
five minutes, washed with 20mM Tris HCl and centrifuged again and the pellet was resuspended 
in PBS-Asparagine with 0.8 x the original sputum volume.   
4.4.3 rTDMH Incubation and RT-PCR 
The samples were treated with 11ug (2ul) rTDMH and a corresponding standard was treated with 
2ul of storage buffer and placed at 37 degrees Celsius for 30 minutes.  Following this, the 
samples were placed on a heat block at 75 degrees Celsius for 20 minutes to inactivate the 
enzyme and other lysate products that could inhibit the RT-PCR.  After heat inactivation the RT-
PCR was set up according to the RT-PCR protocol detailed in 4.4.2 and a subsequent 
electrophoresis gel was run to confirm results seen in RT-PCR data.  
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4.5 AIM #3: TEST THE UTILITY OF RTDMH IN SIMULATED SPUTUM SAMPLE 
SPIKED WITH VIRULENT M. TUBERCULOSIS IN RT-PCR 
Because of the nature of the pathogen, the following was done in Bioscience Tower 3 on the 
University of Pittsburgh campus, in a Biosafety level 3, BSL-3 laboratory facility.   
4.5.1 Spiking Samples with virulent M. tuberculosis 
First, 109 cells were attained. 1ml of growing culture was taken and the optical density (o.d.) was 
measured.  An o.d. of 4 meant 109 cells.  To achieve 109 bacteria, four was divided by the 
measured, o.d. The o.d. of the bacteria used was 0.61. 
 Example:  o.d.= x  4/x= #ml needed to reach 109 cells 
The cells were subsequently spun down at 5K rpm for 10 minutes and the supernatant was 
discarded.  The cells were resuspended in 10ml of PBS (to wash cells) and spun again at 5K rpm 
for 10minutes.  Once again the supernatant was discarded, and cells were resuspended in 1ml 
PBS-Asparagine (4g/L) and transferred to 1.5ml microfuge tube.  The desired dilutions were 
then made.  The sputum samples were spiked with the desired dilution value in 450ul of sputum.  
For example, if the dilution made was 108, then 50ul was added to 450ul of sputum to achieve a 
value of 107 bacteria per ml of sputum.  The dilutions made were 106, 105, 104, 103 per ml of 
sputum. 
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4.5.2 Sputum Clarification 
First, a decontamination fluid was made by mixing equal volumes of sterile 1M NaOH solution 
and 0.1M sodium citrate, and then 5mg N-acetyl-L-cysteine was added per ml.  One volume of 
decontamination fluid was added per volume of sputum sample and placed on a shaker at 25 
degrees Celsius for 20 to 25 minutes, after which the samples were spun down at 12K x g for 5 
minutes, washed with 20mM Tris HCl and centrifuged again and the pellet was resuspended in 
PBS-Asparagine with 0.8 X the original sputum volume.   
4.5.3 rTDMH treatment 
The samples were treated with 11ug (2ul) rTDMH and a corresponding standard was treated with 
2ul of storage buffer and placed at 37 degrees Celsius for 30 minutes.  Following this, the 
samples were placed on a heat block at 75 degrees Celsius for 20 minutes to inactivate the 
enzyme and other lysate products that could inhibit the RT-PCR.  After heat inactivation, the 
RT-PCR was set up according to RT-PCR protocol detailed in 4.4.2, and a subsequent 
electrophoresis gel was run to confirm results seen in RT-PCR data.  
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5.0  RESULTS 
5.1 AIM #1 TEST THE UTILITY OF RTMDH IN RT-PCR BASED DETECTION OF 
M. TUBERCULOSIS USING LIQUID CULTURE OF ATTENUATED M. 
TUBERCULOSIS 
5.1.1 Test the activity of rTDMH that was developed 
107 mc2 7000 bacteria were treated with 50 ug of protein overnight at 37 degrees Celsius.  After 
which, six serial dilutions were made and 10ul of each sample was placed on the 7H11 agar plate 
for 17 days.  Looking at Figure 12, the storage buffer treated bacteria, at -4 there are 
approximately 18 colonies.  If 18 colonies were present from 10ul of a 1mL dilution that meant 
that there were 18 x 106 bacteria per ml.  This was done by multiplying 18 by 100, as 10 ul was 
taken from the original dilution and from there, because it was the -4 dilution, it was multiplied 
by 104, thus giving, 18 X 106.  The same was done with the rTDMH treated plate, which can be 
seen in Figure 13.  There appears to be roughly, 9 colonies at the -3 dilution.  This means there 
are roughly 9 X 105 bacteria per ml.  This is roughly a 2 log difference at 107 bacteria which, 








Figure 10: rTDMH treated MC2 7000 for 17 days to test protein activity 
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5.1.2 Genomic DNA preparation and isolation using rTDMH 
An electrophoresis gel was run to compare the results between the standard laboratory CTAB 





Figure 11: Genomic Isolation using rTDMH Electrophoresis Gel 
Resulting data shows that, first rTDMH can be used to effectively isolate genomic DNA 
from mc2 7000.  Second, that it produces a greater amount of DNA than the commonly used 
technique.  Third, it is a significantly faster technique.  The current technique takes over a day to 




100 bp ladder standard 
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5.1.3 Test the utility of rTDMH in RT-PCR using liquid culture of attenuated M. 
tuberculosis  
The purpose of this experiment was to see if the rTDMH mediated lysate could be successfully 
used in a RT-PCR reaction.  In addition to this, a comparative amplification between rTDMH 
treated and storage buffer treated was desired.  It was expected that the rTDMH lysis would 
result in earlier and greater amplification of the sample versus the standard control. The dilutions 
used were the following, bacteria per 10ul RT-PCR reaction: 104, 103, 102, 10, and 1. Data from 
the RT-PCR were plotted in an Excel© graph to compare the results between the Storage buffer 
standard and the TDM-H treated bacteria. (See Figures 12, 13, 14, 15, and 16). 
 
 



















































































 Tables 1 and 2 below compare the Ct values between those samples treated with storage 
buffer versus those treated with rTDMH.  Ct value is the cycle in which the sample passes the 
threshold.  The threshold is where the sample is amplifying exponentially.  This value is what is 
used to compare the efficacy of the enzyme.  If the samples have a one cycle difference that 
means that there is a two-fold difference between the amounts of DNA.  If there is a 3.3 cycle 
difference that means that there is a 10-fold difference between the concentrations of DNA.  
Figure 17, nicely graphs the Ct value difference between the different samples.  In every sample, 
the rTDMH treated sample has a lower Ct value, meaning it is reaching the threshold sooner.  
Take into considering 103 bacteria per a RT-PCR reaction as an example.  Here it is seen that the 
Ct value of the storage buffer is 36.3, whereas the rTDMH treated sample is 31.98.  This is a 
4.32 cycle difference.  
Table 1: Ct Values for Storage Buffer Treated Samples 
Storage Buffer Cт Cт SD 
1 37.95259 3.502306 
10^2 Undetermined 3.502306 
10^3 36.30987 3.502306 
10^4 34.6563 3.502306 
10^5 29.96415 3.502306 
 
Table 2: Ct Values for rTDMH Treated Samples 
rTDMH Cт Cт SD 
1 37.60346 3.502306 
10^2 35.25035 3.502306 
10^3 31.98085 3.502306 
10^4 31.56207 3.502306 




Figure 17: mc27000 in liquid culture 
The bacteria treated with rTDMH show a significantly higher level of amplification than 
those untreated, and the difference is most pronounced in reaction with 10 bacteria.  As seen in 
figure 14, with 10 bacteria amplification is seen at the 35 cycle in rTDMH treated bacteria, 
whereas the storage buffer control is no longer eliciting any amplification.  There is as well a 
trend that occurs from the highest dilution to the lowest, where at 104 bacteria per reaction; 
amplification from rTDMH treated starts at the 28th cycle. The amplification subsequently begins 
later and later, such that at 1 bacterium, there is little to none seen.  In every sample, the rTDMH 
treated bacteria has a higher and earlier amplification.   
An electrophoresis gel was then run with a 100 base pair ladder to confirm the RT-PCR 
results.  From left to right, the lanes are as follows: 100BP ladder, negative control (NC), 1 
storage buffer (SB), 10 SB, 102 SB, 103 SB, 104 SB, 1 TDMH, 10 TDMH, 102 TDMH, 103 




















Figure 18: Electrophoresis gel of rTDMH and Storage buffer treated mc2 7000 
  
Gel electrophoresis of the DNA in Figure 16 is fully consistent with the plots shown in 
Figures 11-15, in a way their lower Ct values show an increased amplification in bacteria that are 
treated with rTDMH first before the RT-PCR.  Moreover, samples treated with enzyme storage 
buffer had less amplification, which faded away as the bacterial number decreased below 103.  
Overall, these findings show that the attenuated mc2 7000 can be successfully treated with 
rTDMH and subsequently used in a RT-PCR reaction and not only elicit an amplification but a 
greater amplification than the cells that are not treated with rTDMH.  Our next goal was to test 
whether rTDMH could be used in clinically relevant M.tb samples in which bacteria are present 
100 BP  NC  1  10  10 ^2 10 ^3 10 ^4 10 ^4 10 ^3 10 ^2 10  1  PC  
Storage buffer treated TDMH treated 
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in chemically complex environments. We chose to test this in sputum as this is the most common 
clinical sample used for diagnosis of Tuberculosis. 
5.2 AIM #2:  TEST THE UTILITY OF RTDMH IN SIMULATED SPUTUM SAMPLE 
SPIKED WITH ATTENUATED M. TUBERCULOSIS IN RT-PCR  
The purpose of this experiment was to test if the activity of rTDMH was preserved in more 
complex chemical environments. Sputum in particular, is what is most commonly used for 
tuberculosis identification; with that said, if the activity was indeed persevered then it would be a 
promising potential option for tuberculosis diagnosis.  Spiking a sputum sample is the closest 
alternative to an actual clinical sample. In this RT-PCR, the negative control had rTDMH in it as 
well to ensure that it was not the rTDMH that was showing background noise in the gel or 
amplification data. The dilutions of bacteria used were 104, 103, 102, 101 bacteria per RT-PCR 
reaction (see Figures 18, 19, and 20).  
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Figure 19: 104 bacteria per RT-PCR reaction 
 
 






































Figure 21: 10 Bacteria per RT-PCR reaction 
 Tables 3 and 4 depict the samples Ct values along with the average Ct value for each 
sample.  Samples that are labeled: “undetermined”, mean that the sample never reach the 
threshold. With that said, in reality the average Ct value is in fact lower. In addition Figure 22 
compares the average Ct values for the samples.  In the case of 103, although it appears as though 
the storage buffer treated sample has a lower average Ct value, this is not the case as it does not 
take into consideration the undetermined Ct value of the other sample and an accurate average 
was not attained.  The actual average Ct value would be lower.  Again, it is seen that the rTDMH 
treated samples produce a lower Ct value than those treated with the storage buffer.  Take into 
consideration the lowest concentration of bacteria per a RT-PCR reaction. There is roughly 2.01 
cycle difference between the two samples.  Recall that for every cycle difference there is a two-






















Table 3: Storage Buffer Sputum Samples with mc27000 
Storage Buffer Cт Cт2 Cт Mean Cт SD 
10^4 35.7551 36.18729782 35.97119891 1.77002 
10^3 35.36415 Undetermined 35.36415 1.77002 
10^2 38.51189 Undetermined 38.51189 1.77002 
10 38.03784 37.69691086 37.86737543 1.77002 
 
Table 4: rTDMH Treated Sputum Samples with mc27000 
rTDMH  Cт Cт2 Cт Mean Cт SD 
10^4 33.22733 33.17180252 33.19956626 1.77002 
10^3 35.51291 36.52143097 36.017170485 1.77002 
10^2 33.0528 36.89831924 34.97555962 1.77002 
10 36.03351 37.12096405 36.577237025 1.77002 
 
 
Figure 22: mc27000 spike sputum samples in liquid culture 
Results show that although the amplification is not as early as in the in-vitro culture, there 
is still an early amplification seen in samples treated with rTDMH versus those untreated.  An 
electrophoresis gel was then done to compare to the results seen in amplification plots.  Results 















no bands in samples treated with just storage buffer.  To confirm that it is not the rTDMH itself 
that is creating this band, the negative control in the gel has rTDMH in it.  Note the NC, negative 




Figure 23: Electrophoresis Gel of Sputum Samples Spiked with MC2 7000 
 
 Results from AIM 3 led to the question, would similar results be seen in virulent M. 
tuberculosis as well? 
100BP NC PC 10^4 10^4 10^3 10^3 10^2 10^2 10 10 
Storage buffer treated TDMH treated 
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5.3 AIM # 3: TEST THE UTILITY OF RTDMH IN SIMULATED SPUTUM SAMPLE 
SPIKED WITH VIRULENT M. TUBERCULOSIS IN RT-PCR. 
This experiment was done because although mc27000 is very similar to the virulent form, it still 
is not as sturdy as the virulent form. To accurately test the utility of the enzyme in a RT-PCR for 
an actual diagnostic tool, it must be tested in the most natural, typical setting, this being virulent 
M. tuberculosis in sputum.  The dilutions for the RT-PCR reaction were 104, 103, and 102 per 
RT-PCR reaction. The resulting amplification plots can be seen in Figures 22, 23, and 24.  
 

















Figure 25: 103 virulent bacteria per RT-PCR reaction 
 





























 Tables 5 and 6 depict the different Ct values for the samples and their associated average.  
Once again the rTDMH treated samples were producing lower Ct values than those treated with 
storage buffer.  Even at 10 bacteria per a RT-PCR reaction which is the lowest concentration, 
there still is 1.4 cycle difference.  Once again take into consideration that an undetermined value 
means that the sample never reached the threshold and the subsequent average Ct value is not 
truly reflective of the average.   
Table 5: Storage Buffer Treated Sputum Samples with Virulent M.tb 
Storage Buffer Cт Cт2 Cт Mean Cт SD 
10^4 35.22482 36.27316 35.74899 1.817498 
10^3 37.53482 38.08072 37.80777 1.817498 
10^2 37.89077 Undetermined 37.89077 1.817498 
10 33.5439 35.58306 34.56348 1.817498 
 
Table 6: rTDMH Treated Sputum Samples with Virulent M.tb 
rTDMH  Cт Cт2 Cт Mean Cт SD 
10^4 35.62404 34.17641 34.900225 1.817498 
10^3 38.07567 35.94001 37.00784 1.817498 
10^2 34.58217 38.00724 36.294705 1.817498 
10 33.14672 33.20918 33.17795 1.817498 
 
 















Results show an earlier amplification in bacteria that were treated with rTDMH versus 
those that were not treated.  Once again an electrophoresis gel result, seen in Figure 25, was run 
to compare results seen in the amplification plot.  Results here show a clear difference between 
samples treated rTDMH and those with storage buffer.  As the concentration of bacteria 
decreases, a difference is also seen.  At 102 bacteria there is no longer a visible band present in 
the storage buffer treated samples; however, one still is seen, and rather brightly, in samples 





Figure 28: Electrophoresis Gel of virulent bacteria in sputum 
PC NC 100 BP 10^4 10^4 10^3 10^3 10^2 10^2 
Storage buffer treated TDMH treated 
 47 
6.0  CONCLUSION 
Tuberculosis is a disease that affects our entire global community; although it does 
disproportionately affect resource limited areas more, resource rich countries are not excluded 
from the reach of this disease.  This is why it remains an integral part of the World Health 
Organization’s, Millennium Development Goals in number 6 part C [18].  Despite 
advancements, in technology it is one of the most prominent diseases in the world.  WHO 
estimates that over one-third of the world’s population is infected with this disease and this fact 
in and of itself is reason enough to allocate attention to it.  But more than this, an increasing 
number of people are being diagnosed with infectious tuberculosis each year, approximately 9 
million, and of those infected with the pathogen, three million die directly because of the disease 
[3].  Moreover, it is the number one killer of HIV infected individuals, with one out of every 
three deaths of HIV infected individuals being attributable to tuberculosis.   
This disease has been present for thousands of years, and current treatments and 
diagnostic tools are not sufficient to significantly decrease the presence this disease has in our 
global community [1].  The diagnostic tools currently used not only take weeks to yield results 
but in HIV infected patients, sometimes result in false negatives, putting them and others at risk 
for contracting infectious tuberculosis.  Real- time Polymerase Chain Reaction, RT-PCR, is the 
preferred method of disease diagnosis because of its specificity and rapid nature.  The pathogen, 
M. tuberculosis’s, unique membrane structure makes it particularly difficult to use RT-PCR 
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effectively in current real-world diagnosis [12].  Its robust membrane makes it such that 
insufficient DNA is usually obtained to elicit the proper amplification that would be necessary to 
use as a diagnostic tool.   
The purpose of this study was to develop an improved diagnostic tool that could 
potentially be applicable in real-world scenarios, yielding faster, more sensitive and accurate 
results than currently seen in tuberculosis diagnosis today.  Results showed that it is possible to 
use a hydrolase, TDMH, for the glycolipid, TDM, which is found on the cellular membrane of 
M. tuberculosis to disrupt the cellular membrane, lyse it, thus releasing genomic DNA and then 
use that lysate in the RT-PCR tool.  This would solve the problem of insufficient genomic DNA 
that is currently attributed to using RT-PCR.   
Results were consistent in the in-vitro culture samples with MC2 7000, sputum samples 
spiked with MC2 7000 and sputum samples spiked with virulent M. tuberculosis.  In each of 
these scenarios, the TDMH treated samples showed earlier amplification than those that were 
treated with storage buffer.  The difference between the three samples was in the amount of 
amplification seen.  In-vitro samples showed a much higher yield and amplification than those in 
sputum; however, sputum samples are the more real-world environment.  Between sputum 
samples spiked with MC2 7000 and those with virulent M. tuberculosis, the results were more 
similar, although there was a slight earlier amplification and yield in those with the MC2 7000.   
The inconsistency seen in sputum samples could be due to limitations of recovering same 
number bacteria after every clarification process.  Furthermore, its consistency alone may make 
it more difficult to ensure that bacteria are thoroughly mixed.  Also it is difficult to attain precise 
volumes of sputum.  
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 In addition to this, the reason why the amplification may be later in sputum samples 
versus in-vitro culture could be due to bacterial loss in the clarification process.  Because of the 
number of steps involved, every time the sample was washed and the supernatant removed, some 
bacteria could have been lost.  
Due to lack of Mtb-infected sputum, we chose to use Mtb-spiked sputum. Although 
spiking is just one step away from clinical samples, it is noteworthy that spiking doesn’t 
reproduce the embedding of bacteria in the sputum matrix. However, results of the spiked 
sputum are promising and pave the road for further work with clinical samples.  The results show 
that it does successfully yield increased amplification in comparison to those simply treated with 
storage buffer.  This suggests that it has the potential to be used in clinical settings as a 
diagnostic tool for tuberculosis.  Having a simple, quick, sensitive and accurate tool such as this 
to use in diagnosis of tuberculosis could be significant in the fight against the tuberculosis 
epidemic.  If such a tool were used in real-world settings, earlier diagnosis could occur, 
preventing the spread of infectious tuberculosis and reducing the mortality associated with 
tuberculosis.  In addition, HIV infected individuals could be accurately tested for tuberculosis, 
preventing the false negatives that occur.  These false negatives subsequently result in a higher 
risk of attaining active tuberculosis.  If this occurred, tuberculosis associated death in HIV 
infected individuals would decline and given it is the leading cause of death in HIV infected 
individuals, the overall number of deaths of HIV infected individuals would correspondingly 
decrease.  Thus the public health significance of this study is substantial.  Using TDMH with 
RT-PCR could potentially be used as a better diagnostic tool which could result in reducing the 
spread of disease; reducing the mortality associated with disease, especially in in HIV infected 
individuals; and on a broader scale, reduces the economic burden associated with the disease.  
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6.1 FUTURE WORK 
There are more experiments that must be done before it can be definitively said that this 
optimized RT-PCR tool that was developed actually can be applied in real-world settings.  At 
this point it can be successfully used on spiked samples of sputum.  The next step in studying its 
effectiveness is to test it in actual clinical blood, tissue, and sputum samples.  These samples 
would not be artificially spiked with M. tuberculosis, rather the samples would already contain it. 
This would be the ultimate test to see if it is a viable option for an improved diagnostic tool.   
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APPENDIX A 
GLOSSARY OF TERMS 
BSL-2 Laboratory:  suitable for work involving agents of moderate potential hazard to 
personnel and the environment. It includes various bacteria and viruses that cause only mild 
disease to humans, or are difficult to contract via aerosol in a lab setting. (MC2 7000 is used 
here). 
BSL-3 Laboratory: This level is applicable to clinical, diagnostic, teaching, research, or 
production facilities in which work is done with indigenous or exotic agents which may cause 
serious or potentially lethal disease after inhalation. It includes various bacteria, parasites, and 
viruses that can cause severe to fatal disease in humans, but for which treatments exist.  All 
procedures involving the manipulation of infectious materials are conducted within biological 
safety cabinets, specially designed hoods, or other physical containment devices, or by personnel 
wearing appropriate personal protective clothing and equipment. (Virulent M. tuberculosis is 
used here). 
Carbenicillin: a bacteriolytic antibiotic preferred as a selecting agent.  
Clarification: the process by which the sputum is decontaminated.  
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Competent Cells: competence is the ability of a cell to take up extracellular DNA from its 
environment. 
CTAB: Cetrimonium bromide, used in the buffer solution for the extraction of DNA.  It is a 
cationic surfactant. 
Ethidium Bromide: an intercalating agent.  It is used in agarose gel electrophoresis to identify 
DNA when under ultra-violet light. 
Gel Electrophoresis: (Agarose Gel Electrophoresis): The technique of electrophoresis is based 
on the fact that DNA is negatively charged at neutral pH due to its phosphate backbone. For this 
reason, when an electrical potential is placed on the DNA, it will move toward the positive pole.  
Larger molecules will be slowed down more than smaller molecules, since the smaller molecules 
can fit through the holes easier. As a result, a mixture of large and small fragments of DNA that 
has been run through an agarose gel will be separated by size. 
mc2 7000: the non-pathogenic, genetically attenuated form of the virulent M. tuberculosis.  
Approved for BSL-2 laboratory usage. 
Lysis: The disintegration of a cell by rupture of the cell wall or membrane  
Lysate: the product of the lysis. The fluid containing the contents of the lysed cells.  
RT- PCR: a laboratory technique based on the PCR, which is used to amplify and 
simultaneously quantify a targeted DNA molecule. For one or more specific sequences in a DNA 
sample, Real Time-PCR enables both detection and quantification. 
Sodium dodecyl sulfate polyacrylamide: It can be used to aid in lysing cells during DNA 
extraction and for unraveling proteins in SDS-PAGE. It is commonly used in 
preparing proteins for electrophoresis in the SDS-PAGE technique.  This compound works by 
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disrupting non-covalent bonds in the proteins, denaturing them, and causing the molecules to 
lose their native shape (conformation). 
SDS- PAGE:  a protein separation technique that uses sodium dodecyl sulfate.  It is a method of 
separating proteins according to their electrophoretic mobility. 
Sonication: the act of applying sound energy to agitate a sample.  For example, it is used in this 
study to disrupt cell membranes and release cellular contents.  Sonication is also used to 
fragment molecules of DNA, in which the DNA subjected to brief periods of sonication is 
sheared into smaller fragments. 
Transformation: is the genetic alteration of a cell resulting from the direct uptake, incorporation 
and expression of exogenous genetic material (exogenous DNA) from its surroundings and taken 






100BP: 100 Base Pair ladder, used in gel electrophoresis 
AFB:  Acid  Fast Bacilli microscopy 
CB: Carbenicillin 
CTAB: Cetrimonium bromide 
MDR-TB: multiple drug resistant tuberculosis 
NC: negative control 
O.D.: optical density measured in specrophotometer 
PC: positive control 
RT-PCR: Real- Time Polymerase Chain Reaction 
SDS: sodium dodecyl sulfate polyacrylamide 
SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis 
TDM: trehalose 6,6’-dimycolate 
TDMH: hydrolase of trehalose 6,6’-dimycolate 
XDR-TB: extremely drug resistant tuberculosis 
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